- Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules
- French marketing authorization approval for Levidcen
- Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals
- Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer
- Advicenne Announces the Closing of a €16 Million Financing Round
- Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting
- Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy
- Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis
- Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis
- Advicenne announces the registration of its Document De Base in relation to its planned IPO on Euronext’s regulated market in Paris
- Document de base (IOM)
- ADV7103: 6-month data presented at ASN
- Preliminary International Offering Memorandum
- Advicenne launches IPO on Euronext’s regulated market in Paris
- Success of the IPO
- Partial exercise of over – allotment option
- Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs
- Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017
- Host Conference Call : Advicenne Full Year 2017 Results and Business Update
- Advicenne 2017 Financial Results and Operational Perspectives for 2018
- Advicenne publishes its annual financial report
- Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria
- Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe
- 21. Résultats
- 20. Quorum
- 19. Attestation CAC sur les rémunerations
- 17. Rapport des CAC sur l’émission d’actions et valeurs mobilières réservées aux salariés
- 18. Rapport CAC sur l’autorisation d’attribution BSA
- 16. Rapport CAC sur l’émission de BSPCE
- 15. Rapport des CAC sur l’émission de BSA avec suppression du DPS
- 14. Rapport des CAC sur l’émission d’actions et valeurs mobilières avec suppression du DPS de catégorie 2
- 13. Rapport des CAC sur l’émission d’actions et valeurs mobilières avec suppression du DPS de catégorie 1
- 12. Rapport des CAC sur l’émission d’actions et de valeurs mobilières avec maintien-suppression du PDS
- 11. Rapport des CAC sur la réduction du capital
- 10. Rapport des commissaires aux comptes sur les conventions réglementées
- 9. Rapport des commissaires aux comptes sur les comptes annuels IFRS
- 8. Rapport des commissaires aux comptes sur les comptes annuels
- 7. Rapport du Conseil d’Administration
- 6. Déclaration du nombre d’actions et de votes au 14 mai 2018
- 5. Liste des membres du Conseil d’Administration et liste des directeurs généraux
- 4. Rapport financier annuel 2017
- 3. Formulaire de vote par correspondance et procuration
- 2. Texte des résolutions
- 1. Avis de réunion
- Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress
- Financial report 2017 (French only)
- IFRS 2017 (French only)
- Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study
- Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis
- Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation
- Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018
- Advicenne Prepares its Expansion with Highly Experienced Industry Professionals
- Interim Financial Report – June 2018
- Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting
- Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada
- Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes
- Advicenne Publishes its Financial Calendar for 2019
- Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium
- Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)
- Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019
- Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris
- Advicenne Publishes its 2018 Annual Financial Report
- 18. Rapport des CAC sur l’émission d’options de souscription d’actions
- 17. Rapport des CAC sur la réduction du capital
- 16. Rapport des CAC sur l’émission de bons de souscription avec suppression du DPS de catégorie 2
- 15. Rapport des CAC sur la souscription au plan d’épargne
- 14. Rapport des CAC sur l’émission de bons de souscription avec suppression du DPS de catégorie 1
- 13. Rapport des CAC sur l’émission de bons de souscription avec suppression du DPS
- 12. Rapport des CAC sur l’émission de bons de souscription de parts de créateur d’entreprises
- 11. Rapport des CAC sur les actions et valeurs mobilières
- 10. Rapport des CAC sur les conventions réglementées au 31 décembre 2019
- 9. Rapport des CAC sur les comptes IFRS au 31 décembre 2018
- 8. Rapport des CAC sur les comptes annuels au 31 décembre 2018
- 7. Rapport du Conseil d’Administration de l’AGM du 24 mai 2019
- 6. Déclaration des actions et votes au 19 avril 2019
- 5.1. Fiche candidat de l’administrateur de l’AGM du 24 mai 2019
- 5. Liste des membres du Conseil d’Administration à l’AGM du 24 mai 2019
- 4. Rapport financier annuel 2018
- 3. Formulaire de vote par correspondance et procuration
- 2. Texte des résolutions – AGM 24 mai 2019
- 1. Avis de réunion de l’AGM du 24 mai 2019
- Advicenne announces its intention to list on the regulated market of Euronext Brussels
- Financial Annual Report 2018
- Annexe IFRS 2018
- Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels
- Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference
- Financial Visibility and Accelerated Development
- Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC
- Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)
- Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London
- Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck
- Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences
- Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook
- Advicenne Publishes its 2019 Half-Year Financial Report
- Interim financial report – June 2019
- Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress
- Advicenne intends to appoint David Horn Solomon as Chairman of the Board of Directors in line with its International Strategy
- Advicenne’s Lead Candidate Approved for Orphan Drug Designation in the Treatment of Cystinuria in Europe
- Advicenne Publishes its Financial Calendar for 2020
- Advicenne Makes ADV7103 8 mEq and 24 mEq Prolonged-Release Granules Available Within Framework of French Temporary Authorization for Use (TAU) Scheme
- Advicenne Announces the Appointment of André Ulmann as Interim Chief Executive Officer
- Advicenne Reports Full-Year 2019 Financial Results and Confirms Operational Outlook for 2020
- Advicenne Combined Shareholders Meeting to Be Held on May 26 Behind Closed Doors
- Advicenne Gears Up for Accelerated Growth
- 9. Advicenne – Fiche candidat administrateur HHE AGM du 200626
- 10. Déclaration actions votes au 20 avril 2020
- 11. Rapport Financier Annuel 2019
- 15. Rapport CAC résolution 28
- 16. Rapport CAC résolutions 29 à 32 et 36 à 39
- 6. Advicenne – Rapport options – Exercice 2019
- 7. Advicenne- rapport AGA – exercice 2019
- 12. Rapport CAC comptes annuels 2019
- 13. Rapport CAC audit IFRS 2019
- 14. Rapport CAC conventions reglementés 2019
- Résultat de l’AGM – Réponses aux questions des actionnaires
- Résultat de l’AGM – Le procès-verbal de l’AGM, incluant le résultat de vote par résolution
- Avis de convocation paru au BALO, le 11 mai 2020
- 3. Formulaire de vote – AGM 6 mai 2020
- 4. Texte des resolutions – AGM 26 mai 2020
- 5. Rapport Conseil d’Administration – AGM 2020
- 8. Liste membres CA – AGM 26 mai 2020
- 1. Avis convocation actionnaires nominatifs – AGM 26 mai 2020
- 2. Demande d’envoi de documents
- 21. Rapport CAC résolutions 42 et 45
- 22. Rapport CAC Résolutions 43 et 45
- 24. Rapport CAC Résolution 48
- Rapport financier annuel 2019
- 17. Rapport CAC résolutions 33 et 39
- 18. Rapport CAC résolutions 34-35-39
- 19. Rapport CAC résolutions 39 et 49
- 20. Rapport CAC Résolutions 41 et 45
- 23. Rapport CAC Résolutions 44 et 45
- Advicenne Shareholders Adopt All Resolutions Recommended by the Board of Directors at Its Combined Shareholders Meeting
- Advicenne Strengthens Its Financial Structure Through the Implementation of its €20 Million Financing Agreement with the European Investment Bank, with the Drawdown of a First Tranche of €7.5 Million
- Advicenne Presents 2020 Half-Year Financial Report and Provides Update on Outlook and Recent Developments
- Financial Statements IFRS 2019
- Financial Annual Report 2019
- Interim financial report 2020
- Advicenne obtains non-dilutive loan facility of €4.3 million guaranteed by the French State
- Advicenne receives positive CHMP opinion recommending approval of ADV7103 (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)
- Advicenne Announces the Appointment of Peter Meeus as Chief Executive Officer
- Advicenne Provides an Update as its Operations Evolve
- Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe
- Precision on the press release dated March 19, 2021
- 2021 Financial Calendar
- Advicenne Reports its Full-Year Financial Results to December 31, 2020 and Confirms its 2021 Outlook
- Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation
- Avis préalable à l’AGM du 14 juin 2021
- Rapport financier annuel 2020
- Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)
- Les rémunérations versées aux personnes les mieux rémunérées
- Le rapport complémentaire du conseil d’administration relatif à la politique de rémunération du nouveau directeur général
- Le rapport du conseil d’administration à l’AG
- La liste des membres du conseil d’administration
- Le texte des résolutions
- Le rapport des commissaires aux comptes sur les comptes consolidés
- Le rapport des commissaires aux comptes sur les comptes annuels
- Le rapport des commissaires aux comptes sur les conventions réglementées
- Live Broadcast of the Annual General Meeting on June 14th, at 11:00 a.m
- Advicenne provides an update on its activities following its Annual General Meeting
- Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m
- Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons
- Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA
- Advicenne Reports 2021 Half Year Financial Results
- Proposed transfer of the listing of Advicenne’s shares to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels
- Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe
- Advicenne announces positive opinion from the French Transparency Commission (HAS) for its drug Sibnayal™ in dRTA
- Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 17 décembre 2021
- Rapport du Conseil d’Administration à l’Assemblée Générale Ordinaire des Actionnaires du 21 Janvier 2022
- Liste des Membres du Conseil d’Administration et des Directeurs Généraux
- Avis de Convocation – Assemblée Générale Ordinaire des Actionnaires du 21 Janvier 2022
- Formulaire Advicenne
- Ordinary General Meeting of the Shareholders of January 21, 2022 – Sole Resolution
- Advicenne announces its financial calendar for 2022
- Advicenne announces commercialization agreement with FrostPharma AB for Sibnayal™ in the Nordic region
- Advicenne reports 2021 sales up 20% to €3.3 million
- Advicenne ordinary shareholders’ meeting approved the project to transfer Advicenne’s shares listing to the Euronext Growth Paris market and delisting from the regulated market of Euronext Brussels
- Advicenne announces the transfer of its shares from Euronext Paris and Euronext Brussels to Euronext Growth Paris on March 30, 2022
- Advicenne announces the release of results of a study showing improved quality of life in patients living with DRTa and treated by ADV7103
- Advicenne Reports its Financial Results for the Year ended 31 December 2021
- A case report highlights the interest of a long-term treatment with ADV-7103 in dRTA
- Advicenne appoints Philippe Boucheron as Chairman of its Board of Directors
- Advicenne 2021 Universal Registration Document made available
- Document d’Enregistrement Universel 2021
- Advicenne announces the launch of its new website
- Share-purchase program authorized by the Annual General Meeting of June 9, 2022
- Results of the vote at the Annual General Meeting of June 9, 2022
- Advicenne provides an update on its activities following its Annual General Meeting and Board of Directors meeting on June 9, 2022
- Advicenne announces commercialization agreement with Taïba Healthcare for Sibnayal® in Middle-East
- Advicenne announces commercial launch of Sibnayal® in Great Britain
- Bilan semestriel S1 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont
- Advicenne updates on availability of Sibnayal® to patients and caregivers in Great Britain
- Advicenne reports its First Half Financial results as of June 30, 2022
- Half year financial report 2022 and auditors’ report
- Advicenne announces the extension of the intellectual property of its drug Sibnayal®
- Advicenne announces its upcoming participation in two of the most important international investor conferences
- Advicenne announces its financial calendar for 2023
- Advicenne announces the second tranche drawdown of its non-dilutive financing agreement with the EIB
- Advicenne obtains Orphan Drug Designation for ADV7103 in the United States for the treatment of distal Renal Tubular Acidosis (dRTA)
- Bilan semestriel S2 du contrat de liquidité contracté avec la Société de Bourse Gilbert Dupont Paris
- Advicenne reports 2022 sales up 13% to €3.7 million
- Advicenne provides an update on its commercial partnerships in Europe and the Middle East
- Advicenne and SPA announce an exclusive distribution agreement for the marketing of Sibnayal® in Italy, Spain and Portugal
- Advicenne completes European commercial coverage of Sibnayal® through its agreement with Avanzanite Bioscience
- Advicenne announces the launch of Sibnayal® in Denmark
- Advicenne reports its financial results for the year ended December 31, 2022
- Advicenne 2022 Universal Registration Document made available
- 2022 Universal Registration Document
- Advicenne annual combined general meeting of June 8, 2023 – Availability of preparatory documents
- Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting
- Advicenne announces long-term results of the European clinical development program for ADV7103
- Advicenne announces 51% growth in Sibnayal® gross sales in H1 2023 to almost €1.0 million
- Advicenne reports its First Half Financial results as of June 30, 2023 and updates on its activities
- Advicenne announces its participation in several scientific conferences and the presentation of updated clinical results about ADV7103
- Advicenne announces the results of its capital increase with preferential subscription rights
- Advicenne announces its 2024 financial calendar
- Advicenne reports 2023 gross sales up 20% to €4.43 million
- FDA grants Orphan Drug Designation to ADV7103 for the treatment of cystinuria
- Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal®
- 2023 Universal Registration Document
- Advicenne 2023 Universal Registration Document made available
- Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting
- Advicenne announces an 8.8% increase in gross sales for H1 2024 and provides an update on its activities
- Advicenne reports its First Half financial results as of June 30, 2024, and updates on its activities
- Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103
- Advicenne announces its 2025 financial calendar
- Advicenne finalizes agreement with Primex Pharmaceuticals AG
- Advicenne announces 2024 gross sales
- Advicenne reaches a significant milestone with the US FDA in the development of ADV7103 in cystinuria
- Advicenne: Fiscal year 2024 marked by the satisfactory commercial performance of Sibnayal® in Europe and development in the United States
- Advicenne 2024 Universal Registration Document made available
- Innovation & Growth in European Capital Markets Event
- Healthcare Investors Days by France Biotech
- Half-Year Results 2019
- ESPN/IPNA 2019
- Portzamparc Biotech Day
- J.P. Morgan Cazenove annual Small/Mid-Cap CEO/CFO Conference
- CF&B Large & Midcap Event
- Forum ODDO BHF
- J.P. MORGAN
- SFNP
- Biomed Event
- Market Solutions Forum by ESN
- Annual results 2019
- General Meeting
- Half-Year Results 2020
- Frankfurt European MidCap Event
- Forum santé MIDCAPS Gilbert Dupont
- Investor Access Event
- Assemblée Générale
- Conférence BIO US 2022
- Conférence Santé – Gilbert Dupont
- European Society of Pediatric Nephrology – Symposium (Ljubljana, SLOVENIA)
- International Pediatric Nephrology Association – Congress 2022 (Calgary, CANADA)
- Réunion SFAF – Advicenne – résultats semestriels
- Investor Access conference – Paris
- European Midcap Event Paris 2022
- Biotech Agora – soirée du 20 octobre – Résultats semestriels Advicenne
- Jefferies 2022 London Healthcare Conference
- J.P. Morgan HealthCare Conference
- Assemblée Générale – 8 juin 2023 / Annual General Meeting – June 8, 2023
- Publication des résultats annuels 2022 / 2022 full-year financial results
- Publication des résultats semestriels 2023 / 2023 H1 financial results
- Investor Access conference – Paris
- Investor access conference – Paris
- Rare disease day symposium (Hannover, GERMANY)
- 60th ERA congress (Milan, ITALY)
- European Society for Paediatric Nephrology – 55th annual meeting (Vilnius, LITHUANIA)
- UK Kidney Week – UKKW 2023 (Newport, UK)
- RÉUNION SFAF – ADVICENNE – RÉSULTATS ANNUELS
- BIO International Convention – June 5-8, 2023 (Boston, MA)
- TP ICAP Midcap Conference (Paris, FRANCE)
- 16th International Symposium For Sjogren’s Disease (ISSJD)
- BIO CEO & Investor Conference – February 26 & 27 (New York)
- BAPN (British Association for Paediatric Nephrology) Annual Meeting 2024 / March 20-22
- BIO INTERNATIONAL CONVENTION – JUNE 3-6, 2024 (SAN DIEGO, CA)
- Advicenne webcast – ADV7103: managing a US approval pathway to address unmet needs in rare renal disease
- Assemblée Générale – 15 mai 2025 / Annual General Meeting – May 15, 2025
